{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-124616","form_type":"8-K","ticker":"ZBIO","cik":"0001953926","company_name":"Zenas BioPharma, Inc.","filed_at":"2024-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.429811+00:00","generated_at":"2026-05-29T12:13:02.193999+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Zenas provides obexelimab trial updates: Ph3 INDIGO topline end-2025, Ph2 data 2025-2026","bullets":["Phase 3 INDIGO trial in IgG4-RD fully enrolled (over 190 patients); topline results expected year-end 2025.","Phase 2 MoonStone trial in RMS enrolling; 12-week primary endpoint data expected Q3:2025.","Phase 2 SunStone trial in SLE enrolling; 24-week primary endpoint data expected 1H:2026.","Preliminary interim data from Cohort 1 of Phase 2 SApHiAre trial in wAIHA provided.","Company states capitalized for clinical data readouts into Q4:2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-124616","json":"https://secwatch.observer/filing/0001104659-24-124616.json","markdown":"https://secwatch.observer/filing/0001104659-24-124616.md","text":"https://secwatch.observer/filing/0001104659-24-124616.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1953926/000110465924124616/0001104659-24-124616-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1953926/000110465924124616/tm2429902d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T12:13:02.193999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}